Citigroup Inc Precision Biosciences Inc Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.7 - $1.41 $32,652 - $65,772	46,647 New	46,647 $34,000
Q3 2022 Nov 10, 2022	SELL	$1.22 - $40.8 $4,374 - $146,308	-3,586 Reduced 78.23%	998 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.15 - $3.34 $42,270 - $122,768	-36,757 Reduced 88.91%	4,584 $7,000
Q1 2022 May 12, 2022	SELL	$2.96 - $7.76 $410,670 - $1.08 Million	-138,740 Reduced 77.04%	41,341 $127,000
Q4 2021 Feb 10, 2022	BUY	$7.4 - $11.66 $371,924 - $586,031	50,260 Added 38.71%	180,081 $1.33 Million
Q3 2021 Nov 10, 2021	BUY	$9.18 - $14.15 $1.19 Million - $1.84 Million	129,821 New	129,821 $1.5 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $554M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.